On this episode we feature the CEO of Bionyra, Frederic Marrache, after closing French-biotech’s larges ever Series A ($165million) this summer.
Bionyra are a Sofinnova-incubated I&I biotech advancing in-licensed monoclonal (TL1A & IL25) & bispecific (TL1AxIL-23p19) HLE antibodies for a range of autoimmune indications. In this conversation we chat why, after a decade within Sanofi’s I&I development organization, Frederic viewed the Bionyra opportunity as ‘the one’ to scratch his biotech itch.